Ireland Overhauls Biopharma Tariffs to Spur RD and Trade

Ireland Overhauls Biopharma Tariffs to Spur RD and Trade

Ireland has released a biopharmaceutical tariff adjustment plan aimed at reducing R&D and compliance costs, and strengthening its global competitiveness. The new policy focuses on tax reductions for R&D equipment, adaptation to new EU regulations, incentives for high-value drug exports, and restrictions on low-value-added product exports. This move aims to address challenges such as the impact of new EU regulations and increased global competition. It is expected to promote the quality and efficiency of Ireland's biopharmaceutical industry, optimize the global trade landscape, and inject new impetus into Sino-Irish and EU-Irish pharmaceutical trade.

Policy Shifts Urged to Boost Stalled Sustainable Aviation Fuel Growth

Policy Shifts Urged to Boost Stalled Sustainable Aviation Fuel Growth

IATA reports that the growth of Sustainable Aviation Fuel (SAF) production is hindered. Current policies have failed to effectively promote SAF production and application, leading to soaring costs. The mandatory requirements in the EU and the UK serve as negative examples. As e-SAF mandates approach, lessons must be learned to avoid repeating these mistakes. Regulators should promptly correct course and develop effective incentive mechanisms to promote the SAF industry and help the aviation industry achieve its sustainability goals. A focus on incentivizing production rather than solely mandating usage is crucial.